Napsin A Aspartic Peptidase, NAP1, NAPA, Kidney-Derived
Aspartic Protease-Like Protein, Aspartyl Protease 4, TA01/TA02, Napsin-1, SNAPA,
Asp 4, ASP4, CTB-191K22.6,
EC 3.4.23.15, Pronapsin A, EC 3.4.23.5, EC 3.4.23.3, EC
3.4.23.-, EC 3.4.23, Napsin-A, KDAP, KAP,
Napsin-A.
Napsin A Aspartic Peptidase, also known as NAPSA is a member of the
peptidase A1 family. NAPSA is involved in the processing of pneumocyte
surfactant precursors. Furthermore the activation peptides of aspartic proteinases
take part as inhibitors of the active site. These peptide segments/pro-parts are
considered essential for correct folding, targeting, as well as control of the
activation of aspartic proteinase zymogens. The pronapsin A gene is expressed mostly
in lung and kidney. In addition, NAPSA translation product is expected to be a
fully functional, glycosylated aspartic proteinase precursor which contains an
RGD motif as well as an additional 18 residues at its C-terminus.
NAPSA Human Recombinant produced in E.Coli is a single, non-glycosylated
polypeptide chain containing 380 amino acids (64-420 a.a) and having a
molecular mass of 40.9kDa.
NAPSA is fused to a 23 amino acid His-tag at N-terminus
& purified by proprietary chromatographic techniques.
Escherichia Coli.
Sterile filtered colorless solution.
NAPSA protein solution (0.25mg/ml) containing 20mM
Tris-HCl (pH8.0) and 10% glycerol.
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Avoid multiple freeze-thaw cycles.
Greater than 90.0% as determined by SDS-PAGE.
ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
